---
title: "Obefazimod (ABX464) in Ulcerative colitis: ABX464-FE-001"
description: "Formulary evidence on Obefazimod (ABX464) in Ulcerative colitis: ABX464-FE-001. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 24 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence/abx464-fe-001"
published: "2026-11-18T10:42:55-05:00"
modified: "2026-11-18T10:42:55-05:00"
---

# Obefazimod (ABX464) in Ulcerative colitis: ABX464-FE-001

<a id="heading-3.1.14"></a>

## 3.1.14 ABX464-FE-001

<a id="heading-3.1.14.1"></a>

### 3.1.14.1 Objective

<a id="topic-3.1.14.1-1"></a>

#### Objectives stated in the publication

> “The objectives of this study were to assess the relative bioavailability of single and repeated oral doses of 50 mg of ABX464 under fed or fasted conditions and to assess the clinical and biological tolerability of ABX464.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.1-2"></a>

#### Purpose stated in the registry record

> “The goal of this study is to determine the impact of the food on the absorption of the ABX464.”

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.2"></a>

### 3.1.14.2 Location and Study Date

<a id="topic-3.1.14.2-1"></a>

#### Single site in Mauritius, October 2014 to June 2015

> “The study (protocol no. ABX464-FE-001) was approved by the Clinical Research Regulatory Council in Mauritius and conducted between October 2014 and June 2015 in accordance with the Declaration of Helsinki and good clinical practice guidelines.”
> “performed at a single site (CAP Research, Phoenix, Mauritius)”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.2-2"></a>

#### Study dates and status in the registry record

| Field | Registry entry |
| --- | --- |
| Recruitment status | “Completed” |
| Study start | “2014-09” |
| Primary completion (actual) | “2015-06” |
| Other study ID numbers | “ABX464-FE-001” |

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.3"></a>

### 3.1.14.3 Study Design

<a id="topic-3.1.14.3-1"></a>

#### Open-label, randomized food-effect design in two groups

> “This phase I study consisted of an open-label, food-effect, randomized study divided into 2 groups and performed at a single site (CAP Research, Phoenix, Mauritius).”
> “In the first group, a crossover design, 24 subjects received a single dose of 50 mg of ABX464 on 2 occasions (once under fasted conditions [treatment A] and once under fed conditions [treatment B]), separated by a washout period of at least 45 days. In the second group, a parallel design, 24 subjects received 50 mg of ABX464 every 3 days during 10 days under the fasted (treatment A) or fed (treatment B) condition.”
> “The second group involved the repeated-dose investigation with a conservative interval of 3-day dosing being chosen primarily because of safety considerations and also to assess whether this regimen was sufficient to maintain the metabolite at high levels.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.4"></a>

### 3.1.14.4 Eligibility Criteria

<a id="topic-3.1.14.4-1"></a>

#### Healthy men aged 18 to 55 years

> “Forty-eight healthy male subjects in good health on the basis of medical history, physical examination, vital signs, electrocardiogram (ECG), and routine laboratory safety tests, aged from 18 to 55 years, with BMIs of 17 to 28 kg/m2, and who were nonsmokers or light smokers (≤5 cigarettes per day) without history of frequent headache and/or migraine, recurrent nausea, and/or vomiting were included after having given their written informed consent.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.4-2"></a>

#### Key criteria in the registry record

> “Healthy Caucasian male subjects, 18-55 years of age”
> “Subject who will likely be unable to eat entirely the standard high fat breakfast within the allocated time.”

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.5"></a>

### 3.1.14.5 Treatment

<a id="topic-3.1.14.5-1"></a>

#### Obefazimod 50 mg fasted or after a high-fat breakfast

> “In group 1, a single oral dose of ABX464 (50 mg; two 25-mg capsules) was administered on the morning of day 0 of each period either after overnight fasting or after a high-fat breakfast.”
> “In group 2, ABX464 (50 mg) was administered on days 1, 4, 7, and 10 either after overnight fasting or after a high-fat breakfast.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.6"></a>

### 3.1.14.6 Study Outcomes

<a id="heading-3.1.14.6.1"></a>

#### 3.1.14.6.1 Rationale for Using Single-dose AUC and Cmax Under Fed and Fasted Conditions as the Primary Endpoints

<a id="topic-3.1.14.6.1-1"></a>

##### Registered primary and secondary outcomes

| Outcome | Measure | Time frame |
| --- | --- | --- |
| Primary | “Area under the plasma concentration versus time curve (AUC) of single oral dose of 50mg of ABX464 in fed or fasted condition.” | “45 days” |
| Primary | “Peak Plasma Concentration (Cmax) of single oral dose of 50mg of ABX464 in fed or fasted condition.” | “45 days” |
| Secondary | “Number of Subjects with treatment-related adverse events as assessed by CTCAE v4.0” | “Up to 45 days” |

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="topic-3.1.14.6.1-2"></a>

##### Reason for studying the food effect

> “Food influence can be very important in the absorption of medicines, because food can lead to inefficiency in treatment or an increase in adverse events (AEs). It is important to investigate the food effect on the plasma levels of the drug in order to accordingly adapt doses for patients and optimize the treatment.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.7"></a>

### 3.1.14.7 Statistical Analysis Description

<a id="heading-3.1.14.7.1"></a>

#### 3.1.14.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.14.7.1-1"></a>

##### Planned and enrolled participants

> “Twenty-four subjects were enrolled in each group in order to have 20 evaluable subjects per group (data not shown).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.7.1-2"></a>

##### Planned enrollment in the registry record

> “This is a phase I, single-center, open-label, two-treatment, food-effect, randomized study in 40 healthy Caucasian male subjects in order to determine the impact of the food on the absorption of the ABX464.”

Source: [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="heading-3.1.14.7.2"></a>

#### 3.1.14.7.2 Description of Analysis Sets

<a id="topic-3.1.14.7.2-1"></a>

##### Safety and pharmacokinetic populations

> “All of the included subjects received the treatment as planned in the protocol and were analyzed in the safety analysis.”
> “This was considered to have no impact on PK parameters, and thus all the subjects/periods were kept in the PK population except a subject in group 1 with no quantifiable ABX464 plasma concentrations after administration of ABX464 without food (treatment A).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.7.2-2"></a>

##### Statistical comparison of fed and fasted conditions

> “In 2 groups, for each parameter, a point estimate for the ratio of geometric means (GMs) (treatment B to treatment A) was obtained by calculating the difference of least-square means on the logarithmic scale and subsequent back-transformation with the exponential function.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8"></a>

### 3.1.14.8 Results

<a id="heading-3.1.14.8.1"></a>

#### 3.1.14.8.1 Participant Disposition

<a id="topic-3.1.14.8.1-1"></a>

##### Vomiting episodes and treatment received as planned

> “Regarding the PK analysis set, 6 subjects (5 in group 1 and 1 in group 2) experienced vomiting episodes on day 1 more than 2 h after administration.”
> “No AEs led to premature discontinuation.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8.2"></a>

#### 3.1.14.8.2 Baseline Characteristics

<a id="topic-3.1.14.8.2-1"></a>

##### Age and body mass index by group

> “Twenty-four male subjects aged from 20 to 53 years (mean, ∼35 years) and with a body mass index (BMI) of 17.4 to 28.2 kg/m2 were included in group 1, and 24 male subjects aged from 18 to 53 years (mean, ∼34 years) and with a BMI of 17.9 to 28.0 kg/m2 were included in group 2.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8.3"></a>

#### 3.1.14.8.3 Efficacy Results

<a id="topic-3.1.14.8.3-1"></a>

##### Single-dose obefazimod exposure, fed versus fasted (group 1)

| Parameter | Fasted, geometric mean | Fed, geometric mean | Point estimate (fed/fasted) | 90% CI |
| --- | --- | --- | --- | --- |
| Cmax, ng/ml | “13.70” | “43.71” | “3.16” | “2.45–4.07” |
| AUC0–t, ng · h/ml | “34.52” | “109.27” | “3.12” | “2.55–3.82” |

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.8.3-2"></a>

##### Food increased obefazimod exposure and delayed absorption

> “The maximum concentration (Cmax) and the area under the concentration-time curve from time zero to infinity (AUC0–∞) of ABX464 were demonstrated to increase with food after a single dose of ABX464 (219% and 188%, respectively). The apparent terminal elimination half-lives (t1/2s) under fed and fasted conditions were comparable, at about 0.80 h. The median time to maximum concentration (Tmax) was delayed from 1.5 to 2.8 h, and the ratio of the AUC0–∞ obtained under fed conditions to the AUC0–∞ obtained under fasted conditions (Frel) was 2.69.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.8.3-3"></a>

##### Repeated dosing (group 2)

> “Day 1 GM values for Cmax and AUC0–t were 42.92 ng/ml and 105.22 ng · h/ml under fed conditions compared to 10 ng/ml and 26.92 ng · h/ml, respectively, under fasted conditions, i.e., 329% and 291% higher.”
> “With concomitant food intake, GM values of Cmax and AUC0–t were also substantially higher (415% and 294% higher, respectively).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.8.3-4"></a>

##### Smaller food effect on the N-glucuronide metabolite

> “The GM value of the Cmax of ABX464-NGlc given under fed conditions (2,401.52 ng/ml) was 7% lower than that when ABX464 was given under fasted conditions (2,572.81 ng/ml), while the GM AUC0–∞ was 6% lower.”
> “The GM values for Cmax and t1/2 were approximately 190- and 120-fold higher, respectively, than those for the parent compound under fasted conditions.”
> “After the fourth administration, differences in ABX464-NGlc PK parameters under fasted and fed conditions were somewhat larger than those after the first, with GM values for the Cmax and AUC0–t being 35% and 33% higher, respectively, when ABX464 was given with food (Table 5).”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.8.4"></a>

#### 3.1.14.8.4 Health-related Quality of Life and Patient-reported Outcomes

Not applicable.

<a id="heading-3.1.14.8.5"></a>

#### 3.1.14.8.5 Safety Results

<a id="topic-3.1.14.8.5-1"></a>

##### Treatment-emergent adverse events

> “A total of 50 treatment-emergent AEs (TEAEs) (27 under fasted conditions and 23 under fed conditions) were reported by 21 subjects out of 48 (data not shown). All of them were of mild to moderate intensity except for 1 case of severe abdominal injury not related to ABX464. The most frequent TEAEs consisted of headaches (29% of the subjects), nausea (12.5% of the subjects), and vomiting (12.5% of the subjects).”
> “Concomitant food intake did not appear to reduce this side effect, as 4 subjects vomited under fed conditions and 2 under fasting conditions.”
> “There was 1 serious AE (SAE) in each group resulting from an accident and an intercurrent disease (acute gastroenteritis 26 days after the last dosing). None of these could be reasonably related to ABX464.”
> “No changes or clinically significant abnormalities in either laboratory parameters, vital signs, or ECG parameters were observed.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="heading-3.1.14.9"></a>

### 3.1.14.9 Study Limitations

<a id="topic-3.1.14.9-1"></a>

#### Summary

ABX464-FE-001 enrolled 48 healthy men in Mauritius in 2014 and 2015, 24 per group; the registry described 40 healthy Caucasian men. The repeated-dose group received 50 mg every 3 days, a schedule the authors chose for safety reasons, and compared fed and fasted conditions in a parallel design. The authors state that the study “does have a number of intrinsic limitations”: women were excluded, no age effects could be analyzed, and the terminal elimination rate constant after a single dose could be determined in only 17 participants fasted and 13 fed. One participant without quantifiable fasted concentrations was excluded from the pharmacokinetic analysis, and four authors are Abivax employees.

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/); [ClinicalTrials.gov NCT02731885](https://clinicaltrials.gov/study/NCT02731885)

<a id="topic-3.1.14.9-2"></a>

#### Limitations stated by the authors

> “Also, as this study was the first to investigate food effect and repeated dosing, it does have a number of intrinsic limitations.”
> “In addition, in order to eliminate any potential risk in the event of contraceptive failure, female subjects were not included in this study. The study is further limited in that no age effects could be analyzed, as the study was done with low subject numbers (n = 24 in each group), in the 18- to 55-year age group, as is standard for such early studies.”
> “With treatment A (single treatment under fasted conditions), the terminal plasma elimination rate constant (kel) could be properly determined in only 17 subjects.”
> “With treatment B (single treatment under fed conditions), the kel could be properly determined in only 13 subjects.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

<a id="topic-3.1.14.9-3"></a>

#### Funding and author affiliations

> “This work was funded by Abivax, a publicly listed company (formerly known as Splicos).”
> “D.S., J.-M.S., P.G., and H.J.E. are Abivax employees and hold Abivax stock options.”

Source: [Scherrer et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5192114/)

## Related pages
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Terms and abbreviations](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/terms-and-abbreviations.md)
- [Obefazimod (ABX464): Ulcerative colitis](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/executive-summary.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Product information and disease description](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/product-information-and-disease-description.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Clinical evidence](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/clinical-evidence.md)
- [Obefazimod (ABX464) in Ulcerative colitis: Economic information and modeling report](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/economics.md)
- [Obefazimod (ABX464) in Ulcerative colitis: References](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references) · [Markdown](https://www.evicenter.com/drugs/obefazimod--ulcerative-colitis/references.md)
